32385-11-8|Sisomicin|(2R,3R,4R,5R)-2-(((1S,2S,3R,4S,6R)-4,6-diamino-3-(((2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)-5-methyl-4-(methylamino)tetrahydro-2H-pyran-3,5-diol|-范德生物科技公司

Sisomicin

NMR下载 COA and HPLC MSDS下载
names：
(2R,3R,4R,5R)-2-(((1S,2S,3R,4S,6R)-4,6-diamino-3-(((2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)-5-methyl-4-(methylamino)tetrahydro-2H-pyran-3,5-diol
CAS号：
32385-11-8
MDL Number：
MF(分子式)： C19H37N5O7 MW(分子量)： 447.53
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
FMK19550-100mg	100mg	>98%	¥ 3220.00	¥ 3220.00		2 Weeks	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	(2R,3R,4R,5R)-2-(((1S,2S,3R,4S,6R)-4,6-diamino-3-(((2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)-5-methyl-4-(methylamino)tetrahydro-2H-pyran-3,5-diol
英文别名	Sisomicin; Rickamicin; Siseptin;
CAS号	32385-11-8
Inchi	InChI=1S/C19H37N5O7/c1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17/h3,9-18,24-27H,4-7,20-23H2,1-2H3/t9-,10+,11-,12+,13-,14-,15+,16-,17-,18-,19+/m1/s1
InchiKey	URWAJWIAIPFPJE-YFMIWBNJSA-N
分子式 Formula	C19H37N5O7
分子量 Molecular Weight	447.53
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Sisomicin(CAS:32385-11-8):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Sisomicin is an aminoglycoside antibiotic that is highly active against staphylococci.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Tansarli GS, Rafailidis PI, Papazoglou AA, Falagas ME. Antimicrobial activity and clinical effectiveness of sisomicin: an evaluation of the literature (1995-2011). Expert Rev Anti Infect Ther. 2013 Apr;11(4):421-8. doi: 10.1586/eri.13.18. Review. PubMed PMID: 23566151.

[2]Wlasichuk KB, Tan L, Guo Y, Hildebrandt DJ, Zhang H, Karr DE, Schmidt DE Jr. Determination of equilibrium constant of amino carbamate adduct formation in sisomicin by a high pH based high performance liquid chromatography. J Pharm Biomed Anal. 2015;111:126-30. doi: 10.1016/j.jpba.2015.03.033. Epub 2015 Apr 3. PubMed PMID: 25880243.

[3] Kondo J, Koganei M, Maianti JP, Ly VL, Hanessian S. Crystal structures of a bioactive 6'-hydroxy variant of sisomicin bound to the bacterial and protozoal ribosomal decoding sites. ChemMedChem. 2013 May;8(5):733-9. doi: 10.1002/cmdc.201200579. Epub 2013 Feb 21. PubMed PMID: 23436717.

[4] Karaiskos I, Souli M, Giamarellou H. Plazomicin: an investigational therapy for the treatment of urinary tract infections. Expert Opin Investig Drugs. 2015;24(11):1501-11. doi: 10.1517/13543784.2015.1095180. Epub 2015 Sep 30. Review. PubMed PMID: 26419762.

[5] García-Salguero C, Rodríguez-Avial I, Picazo JJ, Culebras E. Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii? Antimicrob Agents Chemother. 2015 Oct;59(10):5959-66. doi: 10.1128/AAC.00873-15. Epub 2015 Jul 13. PubMed PMID: 26169398; PubMed Central PMCID: PMC4576036.

6: Schassan HH. [Antimicrobial effectiveness of sisomicin. I: In vitro activity of sisomicin compared with gentamicin, tobramycin, amikacin and kanamycin (author's transl)]. Infection. 1976;4(2):35-41. German. PubMed PMID: 789246.7: Rodríguez-Avial I, Pena I, Picazo JJ, Rodríguez-Avial C, Culebras E. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains. Int J Antimicrob Agents. 2015 Dec;46(6):616-21. doi: 10.1016/j.ijantimicag.2015.07.021. Epub 2015 Sep 9. PubMed PMID: 26391381.8: Roth S, Naber K, Scheer M, Gruenwaldt G, Lange H. Pharmacokinetics of sisomicin in patients with normal and impaired renal function; its efficacy in urinary tract infection. Eur J Clin Pharmacol. 1976 Sep 30;10(5):357-65. PubMed PMID: 789084.9: Wilczyński S, Pilawa B, Koprowski R, Wróbel Z, Ptaszkiewicz M, Swakoń J, Olko P. EPR studies of free radicals decay and survival in gamma irradiated aminoglycoside antibiotics: sisomicin, tobramycin and paromomycin. Eur J Pharm Sci. 2012 Feb 14;45(3):251-62. doi: 10.1016/j.ejps.2011.11.009. Epub 2011 Nov 17. PubMed PMID: 22115867.10: Davies DH, Mallams AK, Counelis M, Loebenberg D, Moss EL Jr, Waitz JA. Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C. J Med Chem. 1978 Feb;21(2):189-93. PubMed PMID: 413921.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开